PIK3CA and breast cancer: In HR+/HER2- breast cancer, 8.7% (87 of 995) of hotspot alterations associated with an on-label matched therapy were detected at a VAF <5%, comprising alterations in AKT1, ESR1, PIK3CA, and PTEN (Figure 3C).